121 related articles for article (PubMed ID: 26750740)
1. Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplant.
Saillard C; El Cheikh J; Granata A; Coso D; Schiano JM; Bouabdallah R; Blaise D; Charrier N; Broussais F
Leuk Lymphoma; 2016; 57(3):714-6. PubMed ID: 26750740
[No Abstract] [Full Text] [Related]
2. Graft-versus-lymphoma effect plus vorinostat as successful approach in a case of refractory gastric peripheral T cell lymphoma, not otherwise specified, after reduced intensity conditioning allogeneic hematopoietic cell transplant.
Devarakonda SS; Shahan JL; Takalkar A; Chaudhery SI; Jean G; Koshy NV; Hildebrandt GC
Leuk Lymphoma; 2013 Nov; 54(11):2545-7. PubMed ID: 23442066
[No Abstract] [Full Text] [Related]
3. Reduced intensity conditioning allogeneic hematopoietic stem cell transplant could be beneficial to angioimmunoblastic T-cell lymphoma patients with hemophagocytic lymphohistiocytosis.
Yu JT; Hwang WL; Wang RC; Teng CL
Ann Hematol; 2012 May; 91(5):805-807. PubMed ID: 21894473
[No Abstract] [Full Text] [Related]
4. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
Ribrag V; Kim WS; Bouabdallah R; Lim ST; Coiffier B; Illes A; Lemieux B; Dyer MJS; Offner F; Felloussi Z; Kloos I; Luan Y; Vezan R; Graef T; Morschhauser F
Haematologica; 2017 May; 102(5):903-909. PubMed ID: 28126962
[TBL] [Abstract][Full Text] [Related]
5. The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naΪve patients with peripheral T-cell lymphoma: a systematic review of the literature.
Jethwa KD; Bishton MJ; Fox CP
Br J Haematol; 2017 Aug; 178(3):476-479. PubMed ID: 27146257
[No Abstract] [Full Text] [Related]
6. High-dose therapy and stem cell transplantation.
Zinzani PL
Semin Hematol; 2010 Apr; 47 Suppl 1():S15-7. PubMed ID: 20359581
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
8. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.
Lopez G; Liu J; Ren W; Wei W; Wang S; Lahat G; Zhu QS; Bornmann WG; McConkey DJ; Pollock RE; Lev DC
Clin Cancer Res; 2009 May; 15(10):3472-83. PubMed ID: 19417021
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
10. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.
von Tresckow B; Morschhauser F; Szer J; Eichenauer DA; Abramson JS; Sureda A; Engert A
Leuk Lymphoma; 2017 Jan; 58(1):222-225. PubMed ID: 27184350
[No Abstract] [Full Text] [Related]
11. Current and novel treatment options for peripheral T-cell lymphoma.
Horwitz SM
Clin Adv Hematol Oncol; 2015 Jul; 13(7):463-6. PubMed ID: 26353042
[No Abstract] [Full Text] [Related]
12. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
[TBL] [Abstract][Full Text] [Related]
13. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
14. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
15. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
Dickinson M; Ritchie D; DeAngelo DJ; Spencer A; Ottmann OG; Fischer T; Bhalla KN; Liu A; Parker K; Scott JW; Bishton M; Prince HM
Br J Haematol; 2009 Oct; 147(1):97-101. PubMed ID: 19663825
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
[TBL] [Abstract][Full Text] [Related]
17. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
18. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Campbell P; Thomas CM
J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
[TBL] [Abstract][Full Text] [Related]
19. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
Tan D; Phipps C; Hwang WY; Tan SY; Yeap CH; Chan YH; Tay K; Lim ST; Lee YS; Kumar SG; Ng SC; Fadilah S; Kim WS; Goh YT;
Lancet Haematol; 2015 Aug; 2(8):e326-33. PubMed ID: 26688485
[TBL] [Abstract][Full Text] [Related]
20. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
